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Study was not a trial of 
antidepressants
Goodyer et al tell us something about the 
role of cognitive behaviour therapy in 
adolescent depression but nothing about the 
use of drugs.1 
The response rate is not strikingly 
different from what would be expected 
from placebo, and, as with other studies 
of combinations of antidepressant and 
cognitive behaviour therapy,2 we can 
draw no conclusions about the efficacy of 
antidepressants without a placebo arm. 
The authors justify its absence on the basis 
that a placebo arm would be unethical 
in such ill patients. That justification is 
questionable, given that at least 19 out of 20 
studies of newer antidepressants in children 
and adolescents fail to show meaningful 
advantage of drug over placebo on their 
primary outcomes.3 
Although Goodyer et al make few 
direct claims about the effectiveness of 
antidepressants, the implication that benefit 
is attributable to the drug will likely be used 
by others to support prescribing.
Jon N Jureidini head, �e�a���e�� ��� p���h������a� med����e,    
W��e�’� a�d ch��d�e�’� H�����a�, N���h Ade�a�de 5006, 
Au���a��a
jon.jureidini@cywhs.sa.gov.au














Jureidini (previous letter) is correct in 
reminding readers that our trial is not 
a test of the efficacy of fluoxetine over 
psychological treatments. I do not agree 
with his assertion that it is acceptable to use 
a placebo arm in a pragmatic effectiveness 
trial of treatment for adolescent depression.
There is evidence that active treatment 
involving interventions of a psychological 
or a pharmacological nature is effective 
compared with a neutral passive placebo. 
Active psychological treatment is more 
successful than placebo in reducing 
symptoms in the community,1 and 
fluoxetine is effective in accelerating the 
response rate in more moderate to severe 
depression.2 
Under current UK ethical guidelines and 
given the available evidence the use of a 
neutral placebo could be considered to be 
exposing depressed adolescents to greater 
risk than benefit.
I also disagree with Jureidini’s negative 
perspective of the use of fluoxetine and 
would guard against the implications 
of not considering drug treatment in 
depressed adolescents whose condition has 
proved resistant to psychosocial treatment 
approaches or not improved 10 weeks after 
referral. 
A significant proportion of depressed 
young people are hard to treat and 
will become young adults with chronic 
mental illness.3 We require a substantial 
improvement in the evidence base for 
treatment in both community and clinically 
referred patients before definitive treatment 
protocols can be fully developed.
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HanD Hygiene anD tHe cMo
What about reducing turnover?
The chief medical officer (CMO) states that 
hand washing is a major priority and quotes 
examples of poor practice by doctors and 
nurses.1 Like so many before him, he makes 
no mention of overuse of NHS facilities as 
being a critical factor in the battle against 
hospital infections because (presumably) it 
is so politically uncomfortable to do so.
Of course hand washing could be 
improved—but so could ward occupancy 
rates approaching 100% in acute wards. I 
suspect that we will never get significantly 
reduced rates of hospital acquired infection 
until we accept that wards must slow 
down their turnover, a solution which 
local managers cannot consider owing 
to intolerable pressure “from above” to 
improve so called efficiency.
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What about early discharge?
There is good evidence that practising 
hand washing and other decontamination 
techniques helps to reduce the incidence of 
hospital acquired infections.1 There is even 
more literature to suggest that the incidence 
of these infections is high in patients who 
spend more time in hospital because of 
an inability to rehabilitate after acute 
admission.2
So, in addition to emphasising the 
importance of hand washing, the chief 
medical officer (CMO) should emphasise the 
urgent need for early discharge of patients 
admitted to acute hospitals, as well as urging 
the government to provide early discharge 
and support enhanced recovery programmes 
to reduce hospital stay after elective surgery.3
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learn the lessons of the past
Factors other than hand washing contribute 
to hospital acquired infections such as 
changes in hospital practice which were 
designed to improve bed occupancy and 
officially to save money.1
Ward cleaners also used to be part of 
the team in an individual ward under the 
immediate control of the ward sister, who 
ensured that they were taught simple facts 
of hygiene. The cleaners would chat to 
“their patients” and were often told things 
that patients would not mention to the 
doctors. Unfortunately, this function of 
the cleaners could not be factored in by 
accountants, and, to save money, ward 
cleaning was contracted out to private firms. 
The cleaners employed were often less well 
paid, had no personal feeling about any 
ward or its cleanliness, could not be told 
what to do by the ward sister, and had no 
training in hygiene, so the standard of ward 
cleanliness deteriorated.
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Authors’ reply to letter
Neuberger questions our conclusions on 
the Allen Carr Easyway.1 As he points 
out, the observational data on abstinence 
rates are contradictory. This illustrates 
the difficulty of judging the efficacy of 
interventions without clinical trial data. 
Drug companies would not be permitted to 
make the claims of effectiveness made by 
Allen Carr Easyway without having funded 
independent clinical trials. Allen Carr 
Easyway should fund such trials.
Neuberger also suggests that we ignore 
evidence of the harm from nicotine 
replacement therapy (NRT) in pregnancy. 
The literature is insufficient to show whether 
NRT is completely safe and its efficacy in 
pregnancy to confidently recommend it. 
However, given clear evidence of its efficacy 
in non-pregnant populations and  clinical 
reasoning that a lower dose of nicotine 
from NRT is safer than a higher dose 
with additional toxins from cigarettes,2 3 
there should be a presumption of use 
in pregnancy. The UK drug regulatory 
authority also concluded this.
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Some things are just too 
attractive to the media
The Independent on Sunday in its take on 
the Andrew Wakefield General Medical 
Council (GMC) hearings fell back on 
finding a family wrecked by autism.1 2 The 
headline was a quote from a mother of two 
autistic children: “I wish the GMC could 
live a day in my life and see what I have 
seen.” This is presumably a plea that the 
GMC should exonerate Wakefield.
Although the story made all the right 
noises about the lack of evidence for a link 
between MMR and autism, and listed the 
charges against Wakefield, all the emotion 
in the story was biased. In the centre of the 
page was a picture of Wakefield, and under 
it a quote from the story, “My motivation 
is the suffering of children I’ve seen and 
the determination of parents to find out 
why part of them has been destroyed.” The 
best of motives do not excuse unethical 
behaviour, which is what the hearings are 
exploring. In the text but missing from the 
quote is the phrase “devoted, articulate, 
rational” parents. I cannot doubt the first 
two descriptions, but many of these parents 
are not rational in the sense of to weigh 
evidence dispassionately. One parent says, 
“If Wakefield is struck off it will discourage 
any doctor from asking questions about the 
safety of vaccines.” This is an emotional, not 
a rational, response.
Meanwhile, on the previous page to 
Ben Goldacre’s column on this story in the 
Guardian was a story headed “Ban new 
homes near power lines, say MPs.”3 And, 
sure enough, someone had died from brain 
damage, and a relative is convinced the 
power lines were the cause.
Some things, MMR-autism and power 
lines-cancer being examples, are just too 
much of a draw for the media for them to 
be bothered about getting things right.
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suMMary care recorDs
A good idea wrongly introduced
So Winfield believes that all patients should 
be delighted at the idea of electronic 
summary care records.1 If they are such an 
obvious blessing, why not invite patients to 
opt in to the system? She will be knocked 
down in the stampede. This was what the 
BMA and Patient Concern have always 
wanted.
Instead, we have been presented with 
a system of presumed consent where the 
vast majority of patients will have no sight 
of their records to be uploaded. Presumed 
consent is no consent at all, and it is all 
credit to the BMA for recognising this.
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Confusion in the BMA?
Winfield tells us that the BMA is advising 
general practitioners to boycott the 
provision of summary care records.1 So the 
BMA is proposing that the patient must 
actively opt out of the use of his corpse, 
but also proposes to deny said patient the 
opportunity to opt in to the care of his 
live health. As a doctor I don’t get it. As a 
patient I resent it.
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